Vera Therapeutics (VERA) has been drawing attention after a long run of clinical development work in immunological kidney and viral diseases, prompting investors to reassess the stock’s recent performance and risk profile.

Vera Therapeutics’ share price has cooled recently, with a 30 day share price return showing a decline of 4.52% and a 90 day share price return showing a decline of 27.86%, even though the 1 year total shareholder return is 55% and the 3 year total shareholder return is around 4x.

If you are tracking biotech names like Vera Therapeutics and want more ideas with similar potential, it is worth scanning 36 healthcare AI stocks

With Vera Therapeutics trading at $40.16 against an analyst target of $79.00 and an intrinsic value estimate implying an 88% discount, you have to ask: is this a genuine opening, or is future growth already in the price?

Preferred Price to Book of 4.7x: Is it justified?

Vera Therapeutics is trading on a P/B of 4.7x, which screens as expensive against both its biotech peers and the wider group of comparable companies.

The P/B ratio compares the company’s market value to its book value, which is essentially net assets on the balance sheet. For a clinical stage biotech with minimal revenue and ongoing losses, a higher P/B often reflects how much investors are willing to pay for the pipeline, future revenue potential and the strength of the balance sheet to support ongoing trials.

For Vera, the current 4.7x P/B is higher than the peer average of 4.4x and well above the US biotechs industry average of 2.4x. That suggests the market is putting a richer price on Vera’s asset base and pipeline than on many competitors, even though the company is still unprofitable and reports no meaningful revenue.

Result: Price-to-book of 4.7x (OVERVALUED)

However, investors still face meaningful risks, including the company’s clinical trial outcomes, its current lack of revenue, and ongoing net losses of $299.615 million.

Another View: DCF Points the Other Way

While the 4.7x P/B suggests Vera Therapeutics screens as expensive, the SWS DCF model tells a very different story. With the share price at $40.16 compared with an estimated future cash flow value of $338.80, the model indicates the stock is trading at an 88.1% discount. Which signal should matter more to you?

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Vera Therapeutics for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 55 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

Given the mixed signals on valuation and risk, it makes sense to look at the numbers yourself and decide whether the trade off fits your approach, starting with 2 key rewards and 2 important warning signs.

Looking for more investment ideas?

If Vera does not quite fit your plan today, do not stop there. Use focused stock lists to quickly surface other opportunities that match your style.

• Target income potential with reliable cash flows and yield strength by reviewing our 12 dividend fortresses.
• Hunt for quality on sale by scanning the 55 high quality undervalued stocks before prices move away from you.
• Prioritise durability in tougher markets by checking the 75 resilient stocks with low risk scores so you are not last to spot resilient names.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.